Controlled substances: CURES database.
The implementation of AB 1751 will alter existing statutes related to the management of controlled substances, reinforcing the state's capability to monitor prescription drug activities. It enables the Department of Justice to enter agreements for interstate data sharing with other states’ prescription drug monitoring programs. This could enhance the tracking of prescription drugs across state lines, potentially aiding in the fight against prescription drug abuse and ensuring better patient privacy. The bill also ensures compliance with California's stringent data privacy laws, safeguarding patient information.
Assembly Bill 1751 amends sections of the Civil and Health and Safety Codes to enhance the operation and regulatory framework of the Controlled Substance Utilization Review and Evaluation System (CURES) in California. The bill mandates that the Department of Justice establish regulations regarding how information in CURES is accessed and used by healthcare practitioners and other authorized entities. By July 1, 2020, these regulations must be developed through stakeholder consultation, ensuring transparency and community engagement in the process. This legislative move aims to streamline the operation of the CURES database, which is critical for monitoring the prescribing and dispensing of controlled substances.
The sentiment surrounding AB 1751 appears predominantly positive, especially among health care practitioners and law enforcement agencies, who see the bill as a means to improve monitoring and control of prescription drugs. However, concerns have emerged over issues of patient confidentiality and the broader implications of allowing data sharing across state lines. Stakeholder discussions indicate a cautious but supportive view, acknowledging the importance of effective regulation while safeguarding individual privacy rights.
Notable points of contention include the balance between enhanced monitoring and the potential overreach into patient privacy, particularly regarding how data sharing agreements will be established and enforced. Some stakeholders worry that while the intention is to prevent abuse, there could be unintended consequences affecting patient trust in healthcare providers and the confidentiality of sensitive information. Furthermore, the requirement for extensive regulation and stakeholder consultation may delay the implementation timeline proposed in the bill.